Jim Cramer discussed Abbott Laboratories (NYSE:ABT), which has gained 16.7% year-to-date but saw a major dip in July. Despite beating analyst estimates for earnings and revenue, the decision to keep guidance unchanged disappointed investors. Cramer suggested the potential catalyst of the Binax test for Abbott.

After Abbott Laboratories (NYSE:ABT) reported earnings, Cramer expressed disappointment with the mixed update. While the results were solid, management tightened their full-year earnings guidance without raising it, also revising down their organic sales growth forecast and operating margin outlook.

Although ABT shows investment potential, some AI stocks may offer higher returns with limited downside risk. For those seeking an inexpensive AI stock benefiting from Trump tariffs and onshoring, a free report on the best short-term AI stock is available. Explore more stock recommendations for potential growth.

Read more at Yahoo Finance: Jim Cramer Shares Little Known Potential Catalyst For Abbott Laboratories (ABT)